89.83 USD
-0.46 (-0.51%)
90.1 USD
+0.27 (+0.3%)
AZN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AZN has an excellent profitability rating, but there are some minor concerns on its financial health. AZN scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year AZN was profitable.
In the past year AZN had a positive cash flow from operations.
AZN had positive earnings in each of the past 5 years.
In the past 5 years AZN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of AZN (8.21%) is better than 89.53% of its industry peers.
With an excellent Return On Equity value of 20.48%, AZN belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
AZN's Return On Invested Capital of 14.42% is amongst the best of the industry. AZN outperforms 93.72% of its industry peers.
AZN had an Average Return On Invested Capital over the past 3 years of 11.62%. This is in line with the industry average of 12.85%.
The last Return On Invested Capital (14.42%) for AZN is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of AZN (16.17%) is better than 88.48% of its industry peers.
AZN's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 24.34%, AZN belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
AZN's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 81.90%, AZN belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
AZN has about the same amout of shares outstanding than it did 1 year ago.
AZN has more shares outstanding than it did 5 years ago.
AZN has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.45 indicates that AZN is not in any danger for bankruptcy at the moment.
AZN has a better Altman-Z score (3.45) than 70.16% of its industry peers.
The Debt to FCF ratio of AZN is 3.41, which is a good value as it means it would take AZN, 3.41 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.41, AZN belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.
AZN has a Debt/Equity ratio of 0.61. This is a neutral value indicating AZN is somewhat dependend on debt financing.
The Debt to Equity ratio of AZN (0.61) is worse than 67.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.45 |
ROIC/WACC1.64
WACC8.79%
2.3 Liquidity
A Current Ratio of 0.88 indicates that AZN may have some problems paying its short term obligations.
The Current ratio of AZN (0.88) is worse than 87.96% of its industry peers.
AZN has a Quick Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.69, AZN is doing worse than 86.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.61% over the past year.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.17% on average over the next years.
EPS Next Y14.12%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
EPS Next 5Y12.45%
Revenue Next Year10.13%
Revenue Next 2Y8.09%
Revenue Next 3Y7.31%
Revenue Next 5Y7.17%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.53 indicates a rather expensive valuation of AZN.
Based on the Price/Earnings ratio, AZN is valued cheaply inside the industry as 81.15% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.54, AZN is valued a bit cheaper.
AZN is valuated correctly with a Price/Forward Earnings ratio of 16.79.
78.01% of the companies in the same industry are more expensive than AZN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.78. AZN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.53 | ||
| Fwd PE | 16.79 |
4.2 Price Multiples
AZN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AZN is cheaper than 81.68% of the companies in the same industry.
AZN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AZN is cheaper than 80.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.11 | ||
| EV/EBITDA | 14.61 |
4.3 Compensation for Growth
AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of AZN may justify a higher PE ratio.
AZN's earnings are expected to grow with 13.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.38
PEG (5Y)1.05
EPS Next 2Y13.77%
EPS Next 3Y13.01%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.81%, AZN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 5.65, AZN pays a better dividend. On top of this AZN pays more dividend than 92.15% of the companies listed in the same industry.
AZN's Dividend Yield is slightly below the S&P500 average, which is at 2.27.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of AZN has a limited annual growth rate of 1.40%.
AZN has paid a dividend for at least 10 years, which is a reliable track record.
AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
52.89% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
89.83
-0.46 (-0.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner Change11.46%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap278.52B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target96.04 (6.91%)
Short Float %0.33%
Short Ratio1.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)4.9%
PT rev (3m)5.59%
EPS NQ rev (1m)-1.7%
EPS NQ rev (3m)-3.34%
EPS NY rev (1m)0.29%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.53 | ||
| Fwd PE | 16.79 | ||
| P/S | 4.79 | ||
| P/FCF | 29.11 | ||
| P/OCF | 18.4 | ||
| P/B | 6.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.61 |
EPS(TTM)4.6
EY5.12%
EPS(NY)5.35
Fwd EY5.96%
FCF(TTM)3.09
FCFY3.43%
OCF(TTM)4.88
OCFY5.44%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.38
PEG (5Y)1.05
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.45 |
F-Score7
WACC8.79%
ROIC/WACC1.64
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.12%
EPS Next 2Y13.77%
EPS Next 3Y13.01%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.13%
Revenue Next 2Y8.09%
Revenue Next 3Y7.31%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.11%
EBIT Next 3Y17.46%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
What is the fundamental rating for AZN stock?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status of ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ChartMill assigns a valuation rating of 7 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Undervalued.
Can you provide the profitability details for ASTRAZENECA PLC-SPONS ADR?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 19.53 and the Price/Book (PB) ratio is 6.07.
How financially healthy is ASTRAZENECA PLC-SPONS ADR?
The financial health rating of ASTRAZENECA PLC-SPONS ADR (AZN) is 4 / 10.